RICTOR and neoplasm: We utilized clinically relevant mTOR inhibitors capable of mTORC1-selective or dual mTORC1/2 blockade to elucidate the important role of mTORC2 signaling in tumor cell survival and dissected their effects in various TNBC cells harboring RICTOR amplification.